Related references
Note: Only part of the references are listed.OP0043 Twenty-Four Weeks of Treatment with a Novel Anti-IL-6 Receptor Nanobody® (ALX-0061) Resulted in 84% ACR20 Improvement and 58% DAS28 Remission in a Phase I/Ii Study in RA
J.-B. Holz et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors
Sunil Sharma et al.
INVESTIGATIONAL NEW DRUGS (2014)
Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction
Heather A. Huet et al.
MABS (2014)
Evaluation of Pre-existing Antibody Presence as a Risk Factor for Posttreatment Anti-drug Antibody Induction: Analysis of Human Clinical Study Data for Multiple Biotherapeutics
Li Xue et al.
AAPS JOURNAL (2013)
Pre-Existing Biotherapeutic-Reactive Antibodies: Survey Results Within the American Association of Pharmaceutical Scientists
Li Xue et al.
AAPS JOURNAL (2013)
The TRAIL of oncogenes to apoptosis
Eftychia Oikonomou et al.
BIOFACTORS (2013)
Autoantibodies to Variable Heavy (VH) Chain Ig Sequences in Humans Impact the Safety and Clinical Pharmacology of a VH Domain Antibody Antagonist of TNF-α Receptor 1
M. C. Holland et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2013)
A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Luis Paz-Ares et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Novel Antiplatelet Agents: ALX-0081, a Nanobody Directed towards von Willebrand Factor
Jozef Bartunek et al.
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH (2013)
The developing clinical problem of chemotherapy-induced hepatic injury
Charles H. C. Pilgrim et al.
ANZ JOURNAL OF SURGERY (2012)
Phase Ib Study of Drozitumab Combined with First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer
Caio M. Rocha Lima et al.
CANCER INVESTIGATION (2012)
First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: A Phase I/II open-label and double-blind study
George D. Demetri et al.
EUROPEAN JOURNAL OF CANCER (2012)
Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non-Small-Cell Lung Cancer
Jean-Charles Soria et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Chemotherapy-induced Liver Injury in Metastatic Colorectal Cancer: Semiquantitative Histologic Analysis of 334 Resected Liver Specimens Shows That Vascular Injury but not Steatohepatitis Is Associated With Preoperative Chemotherapy
Paul Ryan et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2010)
Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors
H. A. Wakelee et al.
ANNALS OF ONCOLOGY (2010)
Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5)
Andres Forero-Torres et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2010)
A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies
D. Ross Camidge et al.
CLINICAL CANCER RESEARCH (2010)
Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer
Roy S. Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
New insights into apoptosis signaling by Apo2L/TRAIL
F. Gonzalvez et al.
ONCOGENE (2010)
TRAIL-Induced Apoptosis Between Tumor Therapy and Immunopathology
Nadia Corazza et al.
NATURAL COMPOUNDS AND THEIR ROLE IN APOPTOTIC CELL SIGNALING PATHWAYS (2009)
Critical aspects of the Bayesian approach to phase I cancer trials
Beat Neuenschwander et al.
STATISTICS IN MEDICINE (2008)
Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver
Xandra Volkmann et al.
HEPATOLOGY (2007)
Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers
Ruth Plummer et al.
CLINICAL CANCER RESEARCH (2007)
Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake
B Mundt et al.
GUT (2005)
Targeting apoptosis pathways in cancer therapy
IM Ghobrial et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2005)
TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice
CH Hao et al.
CANCER RESEARCH (2004)
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy
A Almasan et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2003)
Targeting death and decoy receptors of the tumour-necrosis factor superfamily
A Ashkenazi
NATURE REVIEWS CANCER (2002)
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications
CS Mitsiades et al.
BLOOD (2001)
Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand
M Jo et al.
NATURE MEDICINE (2000)
Share Paper
